Ep150: Jeff Jonker on the Small Molecule Drug Discovery Renaissance

Episode Summary

Executive Summary: Jeff Yonker, CEO of Belhara Therapeutics, discusses his unconventional path into biotech, the value of transparent relationship-driven business development, and why small-molecule drug discovery is resurging. He explains Belhara’s platform for identifying new protein binding pockets using non-covalent chemoproteomics, the Genentech partnership, and how macro pressures like the IRA and weak funding markets are shaping biotech strategy.

Main Topics: Yonker’s accidental path into biotech and leadership style (Priority: 5/5): Yonker describes moving from public policy/counterterrorism and law into biotech, then learning the industry at Wilson Sonsini and Genentech. He argues his broad, non-scientific background helps him synthesize across disciplines and act as a CEO who connects dots. Why biotech is different from other industries (Priority: 5/5): He emphasizes that science and medicine are ultimately constrained by truth: experimental data, clinical trials, FDA decisions, and market outcomes. This creates a culture where strong evidence matters more than spin, which he sees as both demanding and rewarding. The negotiation and partnership philosophy in biotech (Priority: 4/5): Yonker advocates radical candor, face-to-face collaboration, and long-term relationship management in deals. He argues that because the same people often reappear in different roles across the ecosystem, being decent and transparent is strategically important. Belhara’s platform and chemoproteomics approach (Priority: 5/5): He explains Belhara as a true platform company built on chemoproteomics, using light-activated tags to capture non-covalent small-molecule interactions in whole cells for mass spectrometry analysis. The platform is designed to discover new druggable protein pockets beyond traditional targets. Why small molecules are having a renaissance (Priority: 5/5): Yonker argues that advances in biology and chemistry are expanding the set of tractable protein targets, making old-school small molecules newly relevant. He contrasts this with newer modalities while noting oral small molecules remain highly compelling when they can precisely modulate disease biology. Genentech collaboration and platform validation (Priority: 4/5): Belhara’s collaboration with Genentech reflects external validation of the platform and provides access to hard, clinically relevant biology. Yonker says Genentech proposed tough targets with strong assay support, allowing both sides to learn from the platform early. Macro headwinds, IRA concerns, and optimism (Priority: 4/5): Yonker acknowledges valuation compression, capital scarcity, and IRA-related pricing concerns, especially for small molecules, but remains optimistic because the science is improving and the industry has repeatedly recovered from downturns.

Key Arguments: Biotech rewards people who can work with evidence, not just narrative; truth eventually emerges through experiments, trials, regulators, or markets. A non-scientific background can be an advantage in biotech leadership because it enables broader synthesis across functions and disciplines. Transparency in partnering is more effective than gamesmanship because biotech deals are long-term relationships, not one-off transactions. Belhara is a true platform because it can generate many independent therapeutic shots on goal rather than depending on a few assets. Non-covalent chemoproteomics expands the target universe beyond covalent-only methods and is better suited to many chronic diseases. Small molecules are resurging because there are many biologically validated proteins that remain untapped, and new chemistry lets companies reach previously inaccessible pockets. The Genentech deal validates the platform while also accelerating learning on difficult biology with world-class collaborators. The IRA may reduce economics for small-molecule projects, but highly differentiated, first-in-class medicines should still command strong value if they meaningfully improve patient outcomes. Biotech funding remains under pressure, but the downturn is cyclical and should eventually reverse as the science continues to deliver.

Data Points: Series A financing: $50 million - Belhara came out of stealth in January 2023 with this financing from Versant Ventures and a Genentech partnership. Upfront partnership value: $80 million upfront - Yonker notes Genentech contributed significant upfront capital in the collaboration. Industry experience: ~25 years - Yonker says he has been in the biotech industry for roughly 25 years. Genentech tenure: Almost 7 years - He spent nearly seven years at Genentech learning business development and drug development. Small-molecule drug target coverage: ~600 proteins - Yonker states approved U.S. small-molecule drugs target only about 600 proteins. Literature evidence of binding: ~1,800 proteins - He says there is literature evidence of chemicals binding to roughly 1,800 additional proteins. Biologically validated targets: ~5,000 proteins - He estimates about 5,000 proteins have strong genetic, clinical, or preclinical validation as disease-relevant. Human proteome size: ~20,000 proteins - He cites the approximate number of proteins in the human body. Expanded target universe estimate: ~35,000-40,000 possible protein targets - Yonker mentions protein complexes expand possible target space beyond single proteins. Potentially accessible pockets with cysteine residue: ~35%-40% - He says only this fraction of visible protein pockets may have the cysteine residue needed for covalent approaches. Peak Genentech productivity period: 5 positive phase III studies and 5 approvals in 5 years - Yonker recalls Genentech’s highly productive era during his tenure.

Pivotal Quotes: "There is a truth that comes out... someday there is a truth and it's not just what you say the product is." — Jeff Yonker: On why biotech differs from industries where marketing and spin can outrun evidence. "I really believe in sort of fairly radical candor." — Jeff Yonker: On his negotiation philosophy and why transparency matters in long-term biotech collaborations. "We're the most optimistic people in the world to show up at the office every day, you know, with a 99% failure rate, and believe we're going to be the ones that succeed." — Jeff Yonker: On the mindset required to work in biotech amid high failure rates and market downturns.

Implications: Belhara’s strategy suggests platform-enabled small-molecule discovery could unlock major untapped biology, but success will depend on sustained scientific validation and patient capital. The industry’s near-term economics are challenged, yet the long-term opportunity remains large if companies can deliver clear clinical value.